Arecor Therapeutics PLC (AIM:AREC) announced changes to its board, including the appointment of Simon Ormiston as a non-executive director and chair of the Audit and Risk Committee.
He succeeds Christine Soden, who is stepping down.
Also, chief financial officer David Ellam has now been appointed an executive director.
"I am pleased to welcome the two new members of the Arecor Board, Simon and David," said chair Andy Richards.
"Chistine joined the Board at the IPO and has been a major support to the company ever since. The board is grateful for her contribution."
He added that Ormston has had a long career at PwC and his knowledge of the financial markets, transactions and governance will be "very valuable" to Polarean as the firm continues to grow.
"David has played a constructive and positive leadership role within the executive team at Arecor since he arrived a year ago, working closely with Sarah to run the day-to-day operations of the company ... I look forward to having his broader input at the board."